Literature DB >> 8971002

Herpes simplex virus type 2 inhibition of Fas ligand expression.

S Sieg1, Z Yildirim, D Smith, N Kayagaki, H Yagita, Y Huang, D Kaplan.   

Abstract

Herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) are common human pathogens. In this report we demonstrate the capacity of HSV-2, but not HSV-1, to inhibit the activity and cell surface expression of Fas ligand, an important molecule involved in T-cell apoptosis and cell-mediated cytotoxicity. Cells infected with HSV-2 retained Fas ligand intracellularly instead of expressing it on the cell surface. Addition of anti-Fas antibodies markedly inhibited HSV-2 viral production, suggesting that the capacity of the virus to regulate Fas ligand expression, and thereby programmed cell death, may represent a powerful mechanism for the virus to enhance viral replication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971002      PMCID: PMC190970     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  A 14,700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor.

Authors:  L R Gooding; L W Elmore; A E Tollefson; H A Brady; W S Wold
Journal:  Cell       Date:  1988-05-06       Impact factor: 41.582

Review 2.  Viruses perturb lymphocyte functions: selected principles characterizing virus-induced immunosuppression.

Authors:  M B McChesney; M B Oldstone
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

3.  Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance.

Authors:  M Andersson; S Pääbo; T Nilsson; P A Peterson
Journal:  Cell       Date:  1985-11       Impact factor: 41.582

4.  An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens.

Authors:  H G Burgert; S Kvist
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

5.  An adenovirus glycoprotein binds heavy chains of class I transplantation antigens from man and mouse.

Authors:  C Signäs; M G Katze; H Persson; L Philipson
Journal:  Nature       Date:  1982-09-09       Impact factor: 49.962

6.  Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type.

Authors:  W E Lafferty; R W Coombs; J Benedetti; C Critchlow; L Corey
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

7.  Antiviral effects of recombinant tumour necrosis factor in vitro.

Authors:  J Mestan; W Digel; S Mittnacht; H Hillen; D Blohm; A Möller; H Jacobsen; H Kirchner
Journal:  Nature       Date:  1986 Oct 30-Nov 5       Impact factor: 49.962

Review 8.  Genital herpes simplex virus infections: clinical manifestations, course, and complications.

Authors:  L Corey; H G Adams; Z A Brown; K K Holmes
Journal:  Ann Intern Med       Date:  1983-06       Impact factor: 25.391

9.  Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons.

Authors:  G H Wong; D V Goeddel
Journal:  Nature       Date:  1986 Oct 30-Nov 5       Impact factor: 49.962

10.  Viruses disrupt functions of human lymphocytes. Effects of measles virus and influenza virus on lymphocyte-mediated killing and antibody production.

Authors:  P Casali; G P Rice; M B Oldstone
Journal:  J Exp Med       Date:  1984-05-01       Impact factor: 14.307

View more
  19 in total

1.  Glycoprotein D or J delivered in trans blocks apoptosis in SK-N-SH cells induced by a herpes simplex virus 1 mutant lacking intact genes expressing both glycoproteins.

Authors:  G Zhou; V Galvan; G Campadelli-Fiume; B Roizman
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  The US3 protein kinase of herpes simplex virus 1 mediates the posttranslational modification of BAD and prevents BAD-induced programmed cell death in the absence of other viral proteins.

Authors:  J Munger; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

3.  Reovirus-induced apoptosis is mediated by TRAIL.

Authors:  P Clarke; S M Meintzer; S Gibson; C Widmann; T P Garrington; G L Johnson; K L Tyler
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Herpes simplex virus protein kinase US3 activates and functionally overlaps protein kinase A to block apoptosis.

Authors:  Luca Benetti; Bernard Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-10       Impact factor: 11.205

5.  The stability of herpes simplex virus type I genomes in infected Vero cells undergoing viral induced apoptosis.

Authors:  Ying-Hsiu Su; Xianchao Zhang; Benjamas Aiamkitsumrit; Qiyi Tang; Gerd Maul; Nigel W Fraser; Timothy M Block
Journal:  J Neurovirol       Date:  2006-10       Impact factor: 2.643

Review 6.  Role of the Fas/Fas ligand apoptotic pathway in human immunodeficiency virus type 1 disease.

Authors:  D Kaplan; S Sieg
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

7.  Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis.

Authors:  J Bertin; R C Armstrong; S Ottilie; D A Martin; Y Wang; S Banks; G H Wang; T G Senkevich; E S Alnemri; B Moss; M J Lenardo; K J Tomaselli; J I Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

8.  Inhibition of NF-kappa B activity and cFLIP expression contribute to viral-induced apoptosis.

Authors:  P Clarke; R L Debiasi; S M Meintzer; B A Robinson; K L Tyler
Journal:  Apoptosis       Date:  2005-05       Impact factor: 4.677

9.  The herpes simplex virus 1 US3 protein kinase blocks caspase-dependent double cleavage and activation of the proapoptotic protein BAD.

Authors:  Luca Benetti; Joshua Munger; Bernard Roizman
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Serum apoptosis markers in HIV-infected patients with human herpesvirus type 8 and herpes simplex virus type 2 co-infection.

Authors:  O Dakovic Rode; A Markotic; M Kujundzic Tiljak; S Zidovec Lepej; J Begovac
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-27       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.